Haima Therapeutics receives NHLBI SMARTT program support

Haima Therapeutics has been granted NHLBI SMARTT program support for regulatory affairs and pharmacology/toxicology services to enable progression of SynthoPlate for treatment of traumatic hemorrhage toward IND submission. Haima will be working with RTI International to develop a robust regulatory strategy and prepare for a pre-IND meeting with FDA. Pharmacology/toxicology studies will be carried out with SRI International in early 2018.